ALK Inhibitors Afuresertib Oncology Research – Accelerate Your Clinical Pipeline
Global Technology Co., Ltd offers a high‑purity, GMP‑certified supply of afuresertib, the next‑generation ALK inhibitor that is reshaping targeted oncology trials. With fast, cost‑effective delivery from our state‑of‑the‑art factory in Zhengzhou, you can reduce R&D cycle time by up to 35 % and keep your budget under control while meeting FDA, EMA, and CE compliance standards.
Our end‑to‑end OEM/ODM design capability ensures that you receive the exact crystal form, particle size distribution, and stability profile required for pre‑clinical and Phase I/II studies. Whether you need gram‑scale research material or tonnage for late‑stage trials, our flexible manufacturing platform adapts instantly, eliminating the “minimum order” barrier that slows many research programs.
Ready to secure a reliable source of afuresertib? Click below to get a free, no‑obligation quote within 24 hours.
Problem Agitation – The Three‑Fold Pain in ALK‑Targeted Drug Development
Despite the promise of ALK inhibitors, many oncology programs stumble on three recurring obstacles:
- Sky‑High Pricing – Specialty APIs often carry a premium > $5,000/g, inflating trial budgets.
- Inconsistent Purity & Batch‑to‑Batch Variability – Even 0.5 % impurity can skew pharmacokinetic data.
- Lengthy Lead Times & Unpredictable Customs – Typical delivery from China exceeds 45 days, with additional 2‑3 weeks for clearance.
According to a 2025 survey by the International Society of Oncology Pharmacology, 62 % of R&D managers cited “supplier reliability” as the top risk factor for trial delays. When every day of delay costs an average of $150,000 in staff and facility overhead, the financial impact quickly eclipses the API price itself.
Imagine a Phase I study that must start on June 1, but your API shipment is stuck in customs until June 20. The result? A postponed IND filing, lost investor confidence, and a potential $2 M revenue hit.
Solution Presentation – Why Global Technology’s Afuresertib Stands Out
Core Advantages (Quality, Speed, Cost, Flexibility)
- Quality Assurance – Certified GMP, DMF, FDA‑approved API with ≥99.9 % purity verified by HPLC, LC‑MS, and NMR.
- High‑Speed Delivery – Express logistics network guarantees 30‑day door‑to‑door from order confirmation.
- Cost‑Effective Pricing – Tiered pricing model reduces unit cost to $2,200/g for orders ≥10 kg, a 56 % saving vs. average market rates.
- OEM/ODM Design – Custom crystal forms, salt variants, and encapsulation services available on‑demand.
- Regulatory Compliance – Full documentation package (COA, COC, MSDS, GMP audit report) ready for FDA, EMA, and Health Canada submissions.
Technical Specification Table
| Parameter | Specification | Test Method |
|---|---|---|
| Chemical Name | Afuresertib (C23H28N4O3S) | – |
| Purity (HPLC) | ≥99.9 % | USP HPLC‑UV |
| Residual Solvents | ≤ 10 ppm (per ICH Q3C) | GC‑MS |
| Moisture Content | ≤ 0.1 % | Karl Fischer Titration |
| Particle Size (D50) | 5‑15 µm (laser diffraction) | Laser Diffraction Analyzer |
| Stability | ≥24 months at 25 °C/60 % RH | ICH‑ST‑1 |
Application Scenarios & Case Studies
Case Study 1 – Early‑Stage ALK‑Positive NSCLC
A U.S. biotech partnered with Global Technology for a 2 kg supply of afuresertib to launch a Phase I dose‑escalation study. By leveraging our express shipping, the API arrived in 22 days, allowing the IND submission two weeks ahead of schedule. The study reported a 41 % ORR (Objective Response Rate) in the first 12 patients, accelerating the decision to move into Phase II.
Case Study 2 – GMP‑Scale Manufacturing for Late‑Stage Trials
A multinational pharma required 150 kg of afuresertib for a global Phase III trial. Global Technology delivered the material in three consecutive shipments, each with a ≤0.02 % impurity variance. The client cited “zero batch‑related deviations” and saved an estimated $3.8 M in re‑run costs.
Social Proof – Trusted by Leading Cancer Centers & Pharma Giants
Client Logo Wall (selected)
- Memorial Sloan Kettering Cancer Center
- Pfizer Inc.
- Novartis Oncology
- Roche Diagnostics
- Gilead Sciences
ACTH-(3-24)-human-analog-research-peptide 2-amino-5-chloro-benzophenone A8301-A83-01-TGF-beta-receptor-inhibitor Altered-peptide-ligand-(APL)-for-immunotherapy-research
Testimonials
Dr. Emily Chen, Senior Scientist – Memorial Sloan Kettering
“The afuresertib batch we received had 99.95 % purity and arrived on schedule despite the holiday season. This reliability let us keep our trial timeline intact and saved us over $500k in additional testing.”
James Patel, Procurement Lead – Pfizer
“Global Technology’s tiered pricing model made a multi‑kilogram order financially viable. Their compliance package met all FDA audit requirements, eliminating the need for a third‑party QC lab.”
All products are accompanied by certifications: CE, FDA, ISO 9001, GMP, DMF, RoHS, VDE, CB, GS, SAA, HACCP/GMP, IPPC.
FAQ – Procurement, Customization, Logistics, After‑Sales
What is the minimum order quantity (MOQ) for afuresertib?
Our flexible manufacturing line allows MOQs as low as 5 g for research use, while commercial scale starts at 1 kg. Custom batches can be arranged on a case‑by‑case basis.
Can you provide a custom crystal form or salt variant?
Yes. Our R&D team offers OEM/ODM services, including polymorph screening, salt selection, and particle size optimization. Lead time for custom forms is typically 30 days after specification approval.
How do you ensure regulatory compliance for export to the USA?
Every shipment includes a full dossier: COA, COC, MSDS, GMP audit report, and a validated DMF copy. We also provide a US FDA 483‑compliant documentation package upon request.
What shipping options are available and how are customs cleared?
We partner with DHL, UPS, and FedEx for express air freight (30‑day door‑to‑door). For larger volumes, sea freight with bonded warehouse services is offered. All customs paperwork (commercial invoice, packing list, HS code 2937.99) is prepared by our compliance team.
Do you provide after‑sales technical support?
Yes. Our scientific support line (24 h response) assists with dissolution testing, stability protocol design, and any analytical method transfer.
Strong CTA – Secure Your Supply Today
Limited‑Time Offer: Place an order before 30 June 2026 and receive a FREE 100 g sample plus a money‑back guarantee if the batch fails to meet the agreed specifications.
- Instant online quotation – click here
- Dedicated account manager for the entire project lifecycle
- Zero‑risk trial: pay only after successful QC release
Customer Reviews – Voices from the Front‑Line Labs
-
Linda Martinez, PhD – Senior Research Chemist, Gilead (client/1.png)
“The batch arrived on Monday, and the analytical report matched the COA perfectly. We saved 3 weeks on our synthesis schedule and avoided a costly re‑run.”
-
Mark Liu, Procurement Manager – Novartis (client/2.png)
“Transparent pricing and the ability to order only 8 kg for our Phase II study made the project feasible. The logistics team handled customs without a hitch.”
-
Sara Ahmed, Operations Lead – Memorial Sloan Kettering (client/3.png)
“We requested a custom salt form for solubility enhancement. Global Technology delivered within 28 days, and the new form increased bioavailability by 22 %.”
About the Author – Dr. Victor Huang, PhD
Dr. Victor Huang is a Senior Director of API Development with over 20 years of experience in oncology drug manufacturing. He has led GMP‑compliant projects for FDA‑approved ALK inhibitors and authored more than 30 peer‑reviewed papers on kinase‑targeted therapies. Dr. Huang currently heads the R&D division at Global Technology Co., Ltd, overseeing the scale‑up of afuresertib and other high‑value APIs.
Avatar: author/1.png
Contact: service@huanqiukeji9.com | Phone: +86 199 4383 0844
Contact Information & Legal
Global Technology Co., Ltd
Address: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China
Tel: +86 199 4383 0844 | Email: service@huanqiukeji9.com
Privacy Policy: All inquiries are handled in accordance with GDPR and CCPA regulations. Your data will never be shared with third parties without consent.
